Usefulness of cilostazol versus ticlopidine in coronary artery stenting

Youngsup Yoon, Won Heum Shim, Doo Hee Lee, Wook Bum Pyun, In Jai Kim, Yangsoo Jang, Seung Yun Cho

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

A combination of ticlopidine and aspirin has been accepted as the standard antithrombotic regimen after coronary stenting. However, ticlopidine poses serious side effects such as neutropenia or thrombocytopenia. Cilostazol, a cyclic adenosine monophosphate phosphodiesterase inhibitor, is a novel antiplatelet agent with vasodilatory properties. We compared the efficacy and safety of cilostazol plus aspirin (C+A) with ticlopidine plus aspirin (T+A) in elective coronary stenting. Three hundred patients were randomly assigned to receive C+A or T+A 2 days before stenting. The primary end point was a composite of angiographic stent thrombosis, or major cardiac events (death, myocardial infarction, bypass surgery, repeat intervention) at 30 days. The secondary end points were bleeding vascular complications, neutropenia, thrombocytopenia, or side effects requiring discontinuation of the drugs at 30 days. The primary end point was reached in 1.4% in the C+A group and 2.0% in the T+A group (p = 1.0). The rate of bleeding vascular complications was 1.4% in the C+A group and 2.0% in the T+A group (p = 1.0). The rate of drug-related side effects was not statistically different between the 2 groups but slightly higher in the T+A group than in the C+A group (2.7% vs 0.7%, p = 0.37). However, neutropenia was seen in 2 patients only in the T+A group. As a poststenting antithrombotic, C+A is as effective as T+A in preventing major cardiac events including stent thrombosis, and safer in that it does not cause neutropenia despite the fact that there is no statistical difference in the incidence of adverse effects and complications. Copyright (C) 1999 Excerpta Medica Inc.

Original languageEnglish
Pages (from-to)1375-1380
Number of pages6
JournalAmerican Journal of Cardiology
Volume84
Issue number12
DOIs
Publication statusPublished - 1999 Dec 15

Fingerprint

Ticlopidine
Neutropenia
Coronary Vessels
Aspirin
Thrombocytopenia
Stents
Blood Vessels
Thrombosis
Hemorrhage
Phosphodiesterase Inhibitors
Platelet Aggregation Inhibitors
Drug-Related Side Effects and Adverse Reactions
Reoperation
varespladib methyl
Cyclic AMP
Myocardial Infarction
Safety
cilostazol
Incidence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Yoon, Youngsup ; Shim, Won Heum ; Lee, Doo Hee ; Pyun, Wook Bum ; Kim, In Jai ; Jang, Yangsoo ; Cho, Seung Yun. / Usefulness of cilostazol versus ticlopidine in coronary artery stenting. In: American Journal of Cardiology. 1999 ; Vol. 84, No. 12. pp. 1375-1380.
@article{93e7951192f14ebe803a14c7d4937bb4,
title = "Usefulness of cilostazol versus ticlopidine in coronary artery stenting",
abstract = "A combination of ticlopidine and aspirin has been accepted as the standard antithrombotic regimen after coronary stenting. However, ticlopidine poses serious side effects such as neutropenia or thrombocytopenia. Cilostazol, a cyclic adenosine monophosphate phosphodiesterase inhibitor, is a novel antiplatelet agent with vasodilatory properties. We compared the efficacy and safety of cilostazol plus aspirin (C+A) with ticlopidine plus aspirin (T+A) in elective coronary stenting. Three hundred patients were randomly assigned to receive C+A or T+A 2 days before stenting. The primary end point was a composite of angiographic stent thrombosis, or major cardiac events (death, myocardial infarction, bypass surgery, repeat intervention) at 30 days. The secondary end points were bleeding vascular complications, neutropenia, thrombocytopenia, or side effects requiring discontinuation of the drugs at 30 days. The primary end point was reached in 1.4{\%} in the C+A group and 2.0{\%} in the T+A group (p = 1.0). The rate of bleeding vascular complications was 1.4{\%} in the C+A group and 2.0{\%} in the T+A group (p = 1.0). The rate of drug-related side effects was not statistically different between the 2 groups but slightly higher in the T+A group than in the C+A group (2.7{\%} vs 0.7{\%}, p = 0.37). However, neutropenia was seen in 2 patients only in the T+A group. As a poststenting antithrombotic, C+A is as effective as T+A in preventing major cardiac events including stent thrombosis, and safer in that it does not cause neutropenia despite the fact that there is no statistical difference in the incidence of adverse effects and complications. Copyright (C) 1999 Excerpta Medica Inc.",
author = "Youngsup Yoon and Shim, {Won Heum} and Lee, {Doo Hee} and Pyun, {Wook Bum} and Kim, {In Jai} and Yangsoo Jang and Cho, {Seung Yun}",
year = "1999",
month = "12",
day = "15",
doi = "10.1016/S0002-9149(99)00579-2",
language = "English",
volume = "84",
pages = "1375--1380",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12",

}

Usefulness of cilostazol versus ticlopidine in coronary artery stenting. / Yoon, Youngsup; Shim, Won Heum; Lee, Doo Hee; Pyun, Wook Bum; Kim, In Jai; Jang, Yangsoo; Cho, Seung Yun.

In: American Journal of Cardiology, Vol. 84, No. 12, 15.12.1999, p. 1375-1380.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Usefulness of cilostazol versus ticlopidine in coronary artery stenting

AU - Yoon, Youngsup

AU - Shim, Won Heum

AU - Lee, Doo Hee

AU - Pyun, Wook Bum

AU - Kim, In Jai

AU - Jang, Yangsoo

AU - Cho, Seung Yun

PY - 1999/12/15

Y1 - 1999/12/15

N2 - A combination of ticlopidine and aspirin has been accepted as the standard antithrombotic regimen after coronary stenting. However, ticlopidine poses serious side effects such as neutropenia or thrombocytopenia. Cilostazol, a cyclic adenosine monophosphate phosphodiesterase inhibitor, is a novel antiplatelet agent with vasodilatory properties. We compared the efficacy and safety of cilostazol plus aspirin (C+A) with ticlopidine plus aspirin (T+A) in elective coronary stenting. Three hundred patients were randomly assigned to receive C+A or T+A 2 days before stenting. The primary end point was a composite of angiographic stent thrombosis, or major cardiac events (death, myocardial infarction, bypass surgery, repeat intervention) at 30 days. The secondary end points were bleeding vascular complications, neutropenia, thrombocytopenia, or side effects requiring discontinuation of the drugs at 30 days. The primary end point was reached in 1.4% in the C+A group and 2.0% in the T+A group (p = 1.0). The rate of bleeding vascular complications was 1.4% in the C+A group and 2.0% in the T+A group (p = 1.0). The rate of drug-related side effects was not statistically different between the 2 groups but slightly higher in the T+A group than in the C+A group (2.7% vs 0.7%, p = 0.37). However, neutropenia was seen in 2 patients only in the T+A group. As a poststenting antithrombotic, C+A is as effective as T+A in preventing major cardiac events including stent thrombosis, and safer in that it does not cause neutropenia despite the fact that there is no statistical difference in the incidence of adverse effects and complications. Copyright (C) 1999 Excerpta Medica Inc.

AB - A combination of ticlopidine and aspirin has been accepted as the standard antithrombotic regimen after coronary stenting. However, ticlopidine poses serious side effects such as neutropenia or thrombocytopenia. Cilostazol, a cyclic adenosine monophosphate phosphodiesterase inhibitor, is a novel antiplatelet agent with vasodilatory properties. We compared the efficacy and safety of cilostazol plus aspirin (C+A) with ticlopidine plus aspirin (T+A) in elective coronary stenting. Three hundred patients were randomly assigned to receive C+A or T+A 2 days before stenting. The primary end point was a composite of angiographic stent thrombosis, or major cardiac events (death, myocardial infarction, bypass surgery, repeat intervention) at 30 days. The secondary end points were bleeding vascular complications, neutropenia, thrombocytopenia, or side effects requiring discontinuation of the drugs at 30 days. The primary end point was reached in 1.4% in the C+A group and 2.0% in the T+A group (p = 1.0). The rate of bleeding vascular complications was 1.4% in the C+A group and 2.0% in the T+A group (p = 1.0). The rate of drug-related side effects was not statistically different between the 2 groups but slightly higher in the T+A group than in the C+A group (2.7% vs 0.7%, p = 0.37). However, neutropenia was seen in 2 patients only in the T+A group. As a poststenting antithrombotic, C+A is as effective as T+A in preventing major cardiac events including stent thrombosis, and safer in that it does not cause neutropenia despite the fact that there is no statistical difference in the incidence of adverse effects and complications. Copyright (C) 1999 Excerpta Medica Inc.

UR - http://www.scopus.com/inward/record.url?scp=0032730697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032730697&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)00579-2

DO - 10.1016/S0002-9149(99)00579-2

M3 - Article

C2 - 10606107

AN - SCOPUS:0032730697

VL - 84

SP - 1375

EP - 1380

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12

ER -